John Tsai, a seasoned executive with extensive experience as a chief medical officer at Novartis and Amgen, has been appointed to lead Daiichi Sankyo’s global research and development (R&D) initiatives, effective April 1. This leadership transition comes as Ken Takeshita steps down from his role, marking a significant shift in the company’s strategic direction.
Takeshita’s departure follows a period of intense focus on advancing Daiichi’s oncology pipeline, which has seen both successes and challenges in a competitive landscape. Tsai’s appointment signals a renewed commitment to innovation and growth in R&D, as the company aims to enhance its portfolio and address unmet medical needs. His track record in driving drug development and regulatory strategy will be crucial as Daiichi navigates the complexities of bringing new therapies to market.
Get started today with Solo access →
